CRISPR Therapeutics AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company.
Key Highlights
CRISPR Therapeutics AG (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes, or corrects disease-causing abnormalities at its genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Zug, Switzerland.Scope
- Detailed information on CRISPR Therapeutics AG required for business and competitor intelligence needs
- A study of the major internal and external factors affecting CRISPR Therapeutics AG in the form of a SWOT analysis
- An in-depth view of the business model of CRISPR Therapeutics AG including a breakdown and examination of key business segments
- Intelligence on CRISPR Therapeutics AG's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about CRISPR Therapeutics AG, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to Buy
- Gain understanding of CRISPR Therapeutics AG and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess CRISPR Therapeutics AG as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on CRISPR Therapeutics AG's business structure, strategy and prospects.
Table of Contents
- Company Snapshot
- CRISPR Therapeutics AG: Company Overview
- CRISPR Therapeutics AG: Overview and Key Facts
- CRISPR Therapeutics AG: Overview
- CRISPR Therapeutics AG: Key Facts
- CRISPR Therapeutics AG: Key Employees
- CRISPR Therapeutics AG: Key Employee Biographies
- CRISPR Therapeutics AG: Major Products and Services
- CRISPR Therapeutics AG: Company History
- CRISPR Therapeutics AG: Management Statement
- CRISPR Therapeutics AG: Locations and Subsidiaries
- CRISPR Therapeutics AG: Key Competitors
- CRISPR Therapeutics AG: Company Analysis
- CRISPR Therapeutics AG: Business Description
- CRISPR Therapeutics AG: SWOT Analysis
- CRISPR Therapeutics AG: SWOT Overview
- CRISPR Therapeutics AG: Strengths
- CRISPR Therapeutics AG: Weaknesses
- CRISPR Therapeutics AG: Opportunities
- CRISPR Therapeutics AG: Threats
- CRISPR Therapeutics AG: Corporate Financial Deals Activity
- CRISPR Therapeutics AG: Financial Deals Overview
- CRISPR Therapeutics AG: Targets and Partners
- CRISPR Therapeutics AG: Top Deals 2019 - 2023YTD*
- CRISPR Therapeutics AG: Advisors
- CRISPR Therapeutics AG: Top Legal Advisors
- CRISPR Therapeutics AG: Top Financial Advisors
- CRISPR Therapeutics AG: Mergers and Acquisitions
- CRISPR Therapeutics AG: Capital Raising
- CRISPR Therapeutics AG: Partnership
- CRISPR Therapeutics AG: Recent Developments
- CRISPR Therapeutics AG: News and Events Summary
- CRISPR Therapeutics AG: Corporate Governance
- CRISPR Therapeutics AG: Financial Performance
- CRISPR Therapeutics AG: Market Developments
- CRISPR Therapeutics AG: Regulatory and Legal Events
- CRISPR Therapeutics AG: Research & Development
- CRISPR Therapeutics AG: Strategy and Operations
- Appendix
- Contact the Publisher
- Methodology
- About the Publisher
Table 1: CRISPR Therapeutics AG: Key Facts
Table 2: CRISPR Therapeutics AG: Key Employees
Table 3: CRISPR Therapeutics AG: Company History
Table 4: CRISPR Therapeutics AG: Locations and Subsidiaries
Table 5: CRISPR Therapeutics AG: Key Competitors
Table 6: CRISPR Therapeutics AG: Deal Activity by Deal Type - Volume (TTM*)
Table 7: CRISPR Therapeutics AG: Deal Activity by Deal Type - Volume (2019 - YTD*2023)
Table 8: CRISPR Therapeutics AG: Targets and Partners
Table 9: CRISPR Therapeutics AG: Top Deals 2019 - 2023YTD*
Table 10: CRISPR Therapeutics AG: Legal Advisor Ranking by Value (US$m)
Table 11: CRISPR Therapeutics AG: Financial Advisor Ranking by Value (US$m)
Table 12: CRISPR Therapeutics AG: M&A Volume and Value Trend (2019 - YTD*2023)
Table 13: CRISPR Therapeutics AG: M&A Activity by Geography (2019 - YTD*2023)
Table 14: CRISPR Therapeutics AG: Capital Raising Volume and Value Trend (2019 - YTD*2023)
Table 15: CRISPR Therapeutics AG: Capital Raising by Deal Type (2019 - YTD*2023)
Table 16: CRISPR Therapeutics AG: Partnership Volume and Value Trend (2019 - YTD*2023)
Table 17: CRISPR Therapeutics AG: Partnership Trend by Deal Type (2019 - YTD*2023)
Table 18: CRISPR Therapeutics AG: News and Events Summary
Table 19: CRISPR Therapeutics AG: Corporate Governance
Table 20: CRISPR Therapeutics AG: Financial Performance
Table 21: CRISPR Therapeutics AG: Market Developments
Table 22: CRISPR Therapeutics AG: Regulatory and Legal Events
Table 23: CRISPR Therapeutics AG: Research & Development
Table 24: CRISPR Therapeutics AG: Strategy and Operations
List of Figures
Figure 1: CRISPR Therapeutics AG: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: CRISPR Therapeutics AG: Deal Activity by Deal Type - Volume (2019 - YTD*2023)
Figure 3: CRISPR Therapeutics AG: M&A Volume and Value Trend (2019 - YTD*2023)
Figure 4: CRISPR Therapeutics AG: M&A Activity by Geography (2019 - YTD*2023)
Figure 5: CRISPR Therapeutics AG: Capital Raising Volume and Value Trend (2019 - YTD*2023)
Figure 6: CRISPR Therapeutics AG: Capital Raising by Deal Type (2019 - YTD*2023)
Figure 7: CRISPR Therapeutics AG: Partnership Volume and Value Trend (2019 - YTD*2023)
Figure 8: CRISPR Therapeutics AG: Partnership Trend by Deal Type (2019 - YTD*2023)
